4//SEC Filing
McWherter Charles 4
Accession 0000950170-24-035470
CIK 0001042074other
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 5:06 PM ET
Size
30.0 KB
Accession
0000950170-24-035470
Insider Transaction Report
Form 4
McWherter Charles
Sr. Vice President
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−44,084→ 0 totalExercise: $1.82Exp: 2026-07-24→ Common Stock (44,084 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−97,222→ 0 totalExercise: $1.72Exp: 2027-01-18→ Common Stock (97,222 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−300,000→ 0 totalExercise: $7.80Exp: 2033-01-24→ Common Stock (300,000 underlying) - Disposition to Issuer
Common Stock
2024-03-22−15,000→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−172,891→ 0 totalExercise: $8.43Exp: 2029-01-28→ Common Stock (172,891 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−328,299→ 0 totalExercise: $4.05Exp: 2030-05-14→ Common Stock (328,299 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−112,000→ 0 totalExercise: $5.78Exp: 2031-01-25→ Common Stock (112,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−225,000→ 0 totalExercise: $2.94Exp: 2032-01-24→ Common Stock (225,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−51,750→ 0 totalExercise: $1.06Exp: 2026-01-25→ Common Stock (51,750 underlying) - Disposition to Issuer
Common Stock
2024-03-22−31,938→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−146,875→ 0 totalExercise: $11.69Exp: 2028-01-23→ Common Stock (146,875 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−91,666→ 0 totalExercise: $10.00Exp: 2025-01-06→ Common Stock (91,666 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−118,625→ 0 totalExercise: $22.85Exp: 2034-01-23→ Common Stock (118,625 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
- [F2]Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
- [F3]Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Documents
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
Related Parties
1- filerCIK 0001588862
Filing Metadata
- Form type
- 4
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 5:06 PM ET
- Size
- 30.0 KB